Impact of RYALTRIS® Nasal Spray on Patients' Reported Outcomes

WithdrawnOBSERVATIONAL
0
Timeline

Start Date

November 17, 2021

Primary Completion Date

March 14, 2022

Study Completion Date

March 14, 2022

Conditions
Allergic Rhinitis
Interventions
OTHER

Observational

In this observational study, participants with moderate to severe Allergic Rhinitis who were initiated on Ryaltris® nasal spray by their healthcare professional will complete an online survey before commencement of treatment and then at days 1, 7, and 14 from treatment initiation. Survey completion at day 28 after treatment initiation will be optional for participants based on ongoing use of RYALTRIS®.

Trial Locations (1)

2000

Community and Patient Preference Research Pty Ltd, Sydney

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Seqirus Limited

UNKNOWN

collaborator

Glenmark Pharmaceuticals

UNKNOWN

lead

Community and Patient Preference Research Pty Ltd

INDUSTRY

NCT05129306 - Impact of RYALTRIS® Nasal Spray on Patients' Reported Outcomes | Biotech Hunter | Biotech Hunter